ORIGINAL ARTICLE

Cancer Chemotherapy and Pharmacology

, Volume 43, Issue 2, pp 141-144

A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia

  • Steven H. BernsteinAffiliated withRoswell Park Cancer Institute, Elm and Carlton Street, Buffalo, Ny 14263, USA Tel.: +1-716-845-7611; Fax: +1-716-845-8446
  • , Joseph FayAffiliated withBaylor/Saammons Cancer Center, Dallas, TX, USA
  • , Stanley FrankelAffiliated withRoswell Park Cancer Institute, Elm and Carlton Street, Buffalo, Ny 14263, USA Tel.: +1-716-845-7611; Fax: +1-716-845-8446
  • , Neal ChristiansenAffiliated withRoswell Park Cancer Institute, Elm and Carlton Street, Buffalo, Ny 14263, USA Tel.: +1-716-845-7611; Fax: +1-716-845-8446
  • , Maria R. BaerAffiliated withRoswell Park Cancer Institute, Elm and Carlton Street, Buffalo, Ny 14263, USA Tel.: +1-716-845-7611; Fax: +1-716-845-8446
  • , Cindy JacobsAffiliated withImmunex Corporation, Seattle, WA, USA
  • , Consuelo BloschAffiliated withImmunex Corporation, Seattle, WA, USA
  • , Roberta HannaAffiliated withImmunex Corporation, Seattle, WA, USA
  • , Geoffrey HerzigAffiliated withRoswell Park Cancer Institute, Elm and Carlton Street, Buffalo, Ny 14263, USA Tel.: +1-716-845-7611; Fax: +1-716-845-8446

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose: The recombinant human interleukin-1 receptor (rhu IL-1R) is a soluble truncated form of the type 1 full-length membrane-bound receptor that binds IL-1 with identical affinity to that of the membrane form. As such, it may have clinical potential by sequestering IL-1, thereby preventing it from binding to its membrane-bound receptor and eliciting a biological effect. As IL-1 has been shown to regulate leukemic cell proliferation in an autocrine fashion, a phase I trial of rhu IL-1R was conducted in patients with relapsed and refractory acute myeloid leukemia (AML). Methods: The study group comprised 11 patients who were sequentially treated on one of three dose levels, receiving a single intravenous (i.v.) bolus dose on day 1 followed by 13 days of daily subcutaneous (s.c.) injections with the option of an additional 14 days of treatment if a response of stable disease or better was achieved. Dose level 1 i.v. bolus 500 \(\)g/m2, s.c. dose 250 \(\)g/m2 per day (five patients); dose level 2 i.v. bolus 1000 \(\)g/m2, s.c. dose 500 \(\)g/m2 per day (three patients); dose level 3 i.v. bolus 2000 \(\)g/m2, s.c. dose 1000 \(\)g/m2 per day (three patients). Owing to limited drug availability, the study was designed to only examine these three dose levels. Results: rhu IL-1R was well tolerated. There was no grade 3 or 4 non-hematological toxicity related to the study drug and the maximum tolerated dose was not reached. No IL-1R-blocking antibodies developed during the course of the study. Serum levels of IL-1\(\), IL-6 and TNF were undetectable before, during and after rhu IL-1R administration. The terminal half-life after i.v. dosing was at least 7–12 h, and after s.c. dosing 2–4 days. Serum levels of rhu IL-1R up to 360- and 25-fold those of pretreatment levels were achieved after i.v. and s.c. dosing respectively. No patient had a complete, partial or minor response to treatment; four had stable disease and seven had progressive disease. Conclusions: rhu IL-1R therapy was safe but did not have any apparent antileukemic effect at the doses administered.

Key words Interleukin-1   Interleukin-1 receptor  Acute myeloid leukemia   Phase I